JP7178360B2 - 冠状動脈障害を治療するための短鎖型デヒドロゲナーゼ活性の阻害剤 - Google Patents

冠状動脈障害を治療するための短鎖型デヒドロゲナーゼ活性の阻害剤 Download PDF

Info

Publication number
JP7178360B2
JP7178360B2 JP2019554986A JP2019554986A JP7178360B2 JP 7178360 B2 JP7178360 B2 JP 7178360B2 JP 2019554986 A JP2019554986 A JP 2019554986A JP 2019554986 A JP2019554986 A JP 2019554986A JP 7178360 B2 JP7178360 B2 JP 7178360B2
Authority
JP
Japan
Prior art keywords
alkyl
aryl
pgdh
weight
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019554986A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020516617A5 (https=
JP2020516617A (ja
Inventor
マーコウィッツ，サンフォード
ジン ホ，ウォン
ユアン，イエン
ジェイン，ムケシュ
サーベ，モハメッド
レディー，ジョセフ
ウィリアムズ，ノエル
Original Assignee
ケース ウエスタン リザーブ ユニバーシティ
ボード オブ リージェンツ オブ ザ ユニバーシティ オブ テキサス
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ケース ウエスタン リザーブ ユニバーシティ, ボード オブ リージェンツ オブ ザ ユニバーシティ オブ テキサス filed Critical ケース ウエスタン リザーブ ユニバーシティ
Publication of JP2020516617A publication Critical patent/JP2020516617A/ja
Publication of JP2020516617A5 publication Critical patent/JP2020516617A5/ja
Priority to JP2022119729A priority Critical patent/JP2022141930A/ja
Application granted granted Critical
Publication of JP7178360B2 publication Critical patent/JP7178360B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2019554986A 2017-04-07 2018-04-09 冠状動脈障害を治療するための短鎖型デヒドロゲナーゼ活性の阻害剤 Active JP7178360B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022119729A JP2022141930A (ja) 2017-04-07 2022-07-27 冠状動脈障害を治療するための短鎖型デヒドロゲナーゼ活性の阻害剤

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762483177P 2017-04-07 2017-04-07
US62/483,177 2017-04-07
PCT/US2018/026739 WO2018187810A1 (en) 2017-04-07 2018-04-09 Inhibitors of short-chain dehydrogenase activity for treating coronary disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022119729A Division JP2022141930A (ja) 2017-04-07 2022-07-27 冠状動脈障害を治療するための短鎖型デヒドロゲナーゼ活性の阻害剤

Publications (3)

Publication Number Publication Date
JP2020516617A JP2020516617A (ja) 2020-06-11
JP2020516617A5 JP2020516617A5 (https=) 2020-07-30
JP7178360B2 true JP7178360B2 (ja) 2022-11-25

Family

ID=63712743

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019554986A Active JP7178360B2 (ja) 2017-04-07 2018-04-09 冠状動脈障害を治療するための短鎖型デヒドロゲナーゼ活性の阻害剤
JP2022119729A Pending JP2022141930A (ja) 2017-04-07 2022-07-27 冠状動脈障害を治療するための短鎖型デヒドロゲナーゼ活性の阻害剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022119729A Pending JP2022141930A (ja) 2017-04-07 2022-07-27 冠状動脈障害を治療するための短鎖型デヒドロゲナーゼ活性の阻害剤

Country Status (7)

Country Link
US (2) US11426420B2 (https=)
EP (1) EP3606520A4 (https=)
JP (2) JP7178360B2 (https=)
CN (1) CN110891568A (https=)
AU (1) AU2018249956B2 (https=)
CA (1) CA3059255A1 (https=)
WO (1) WO2018187810A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014342811B2 (en) 2013-10-15 2019-01-03 Board Of Regents Of The University Of Texas System Compositions and methods of modulating short-chain dehydrogenase activity
CN118059093A (zh) 2015-03-08 2024-05-24 卡斯西部储备大学 用于治疗纤维症的短链脱氢酶活性的抑制剂
JP7595413B2 (ja) 2016-11-30 2024-12-06 ケース ウエスタン リザーブ ユニバーシティ １５－ｐｇｄｈ阻害剤とコルチコステロイドおよび／またはｔｎｆ阻害剤との組み合わせならびにその使用
WO2018145080A1 (en) 2017-02-06 2018-08-09 Case Western Reserve University Compositions and methods of modulating short-chain dehydrogenase activity
CA3059255A1 (en) 2017-04-07 2018-10-11 Case Western Reserve University Inhibitors of short-chain dehydrogenase activity for treating coronary disorders
CN120463721A (zh) * 2018-11-21 2025-08-12 卡斯西部储备大学 调节短链脱氢酶活性的组合物和方法
CA3168494A1 (en) 2020-01-23 2021-07-29 Roopa Rai Pgdh inhibitors and methods of making and using
CR20220654A (es) 2020-05-20 2023-08-24 Rodeo Therapeutics Corp Composiciones y métodos para modular la actividad de deshidrogenasas de cadena corta
US20230210829A1 (en) * 2020-06-11 2023-07-06 The Board Of Trustees Of The Leland Stanford Junior University Rejuvenation of aged tissues by inhibition of the pge2 degrading enzyme, 15-pgdh
CA3190602A1 (en) * 2020-08-07 2022-02-10 Case Western Reserve University Inhibitors of short-chain dehydrogenase activity for treating neurodegeneration
WO2025170936A1 (en) * 2024-02-05 2025-08-14 The Board Of Trustees Of The Leland Stanford Junior University Materials and methods for treating cardiac dysfunction

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005515182A (ja) 2001-11-16 2005-05-26 ファルマシア アンド アップジョン カンパニー リミティド ライアビリティー カンパニー 抗腫瘍剤により誘導される心臓毒性を処置するためのデクスラゾキサン
US20110269954A1 (en) 2008-12-30 2011-11-03 Hoon Cho Novel thiazolidinedione derivative and use thereof
WO2016168472A1 (en) 2015-04-14 2016-10-20 Case Western Reserve University Compositions and methods of modulating short-chain dehydrogenase activity

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR80916B (en) 1983-11-14 1985-03-12 Dow Chemical Co Method of preparing 1,2,4-triazolo (1,5-a)-pyrimidine-2-sulfonyl chlorides
DE59008552D1 (de) 1989-01-11 1995-04-06 Ciba Geigy Ag Antidots zur Verbesserung der Kulturpflanzenvertäglichkeit agrochemischer Wirkstoffe.
EP0434624B1 (de) 1989-12-22 1995-02-08 Ciba-Geigy Ag Triazolylsulfonamide
SE9303444D0 (sv) 1993-10-20 1993-10-20 Kabi Pharmacia Ab New use of prostaglandins
US6080772A (en) 1995-06-07 2000-06-27 Sugen, Inc. Thiazole compounds and methods of modulating signal transduction
ATE266397T1 (de) 1997-02-04 2004-05-15 Murray A Johnstone Verfahren zur förderung des haarwuchses und entwicklung des haarsystems
EP1558252B1 (en) 2002-08-02 2007-10-10 Merck & Co., Inc. Substituted furo [2,3-b]pyridine derivatives
WO2004089471A2 (en) 2003-04-11 2004-10-21 Novo Nordisk A/S NEW PYRAZOLO[1,5-a] PYRIMIDINES DERIVATIVES AND PHARMACEUTICAL USE THEREOF
EP1615667A2 (en) 2003-04-11 2006-01-18 Novo Nordisk A/S Combinations of an 11-beta-hydroxysteroid dehydrogenase type 1 inhibitor and a glucocorticoid receptor agonist
JP2006522750A (ja) 2003-04-11 2006-10-05 ノボ　ノルディスク　アクティーゼルスカブ 代謝性症候群ならびに関連の疾患および障害を治療するために、１１β−ヒドロキシステロイドデヒドロゲナーゼ１型阻害剤および抗高血圧剤を使用する併用療法
US7189724B2 (en) 2003-04-15 2007-03-13 Valeant Research And Development Quinoxaline derivatives having antiviral activity
EA009920B1 (ru) 2003-08-29 2008-04-28 Вернэлис (Кембридж) Лимитед Соединения пиримидотиофена
JP2008507518A (ja) 2004-07-22 2008-03-13 ピーティーシー セラピューティクス，インコーポレーテッド Ｃ型肝炎を治療するためのチエノピリジン
WO2006078676A2 (en) 2005-01-19 2006-07-27 Merck & Co., Inc. Bicyclic pyrimidines as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
BRPI0620205A2 (pt) 2005-12-20 2011-11-01 Richter Gedeon Nyrt novos compostos
WO2009073460A2 (en) 2007-12-03 2009-06-11 Bausch & Lomb Incorporated Inhibition of 11 beta-hydroxysteroid dehydrogenase type 1 for ocular neuroprotection
CA2709784A1 (en) 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
US9216983B2 (en) 2007-12-21 2015-12-22 Board Of Regents, University Of Texas System Dihydroorotate dehydrogenase inhibitors with selective anti-malarial activity
JP5818266B2 (ja) 2009-09-29 2015-11-18 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム ジヒドロオロット酸デヒドロゲナーゼの阻害剤である抗マラリア剤
GB201107197D0 (en) 2011-04-28 2011-06-15 Cxr Biosciences Ltd Compounds
EP2758544B1 (en) 2011-09-23 2017-10-18 Academisch Medisch Centrum Materials and methods for prognosis of progression of barrett's esophagus
WO2013112699A2 (en) 2012-01-25 2013-08-01 Proteostasis Therapeutics, Inc. Proteasome activity enhancing compounds
US9801863B2 (en) 2012-04-16 2017-10-31 Case Western Reserve University Inhibitors of short-chain dehydrogenase activity for modulating hematopoietic stem cells and hematopoiesis
DK2838533T3 (da) * 2012-04-16 2017-11-27 Univ Case Western Reserve Sammensætninger og fremgangsmåder til at modulere 15-pgdh-aktivitet
AU2014342811B2 (en) 2013-10-15 2019-01-03 Board Of Regents Of The University Of Texas System Compositions and methods of modulating short-chain dehydrogenase activity
CA2966577C (en) 2013-11-19 2023-09-26 Zhongren ZHOU Combined cytology and molecular testing for early detection of esophageal adenocarcinoma
US10144742B2 (en) 2014-04-18 2018-12-04 Millennium Pharmaceuticals, Inc. Quinoxaline compounds and uses thereof
EP3179995B1 (en) 2014-08-12 2018-11-07 University of Pécs (Pécsi Tudományegyetem) Methods and materials for reducing ischemia-reperfusion injury
CN118059093A (zh) 2015-03-08 2024-05-24 卡斯西部储备大学 用于治疗纤维症的短链脱氢酶活性的抑制剂
EP3423067B1 (en) * 2016-03-04 2025-07-23 The Board of Trustees of the Leland Stanford Junior University Inhibitors of 15-hydroxyprostaglandin dehydrogenase for muscle regeneration
CA3031091A1 (en) 2016-07-18 2018-01-25 Case Western Reserve University Inhibitors of short-chain dehydrogenase activity for promoting neurogenesis and inhibiting nerve cell death
JP7595413B2 (ja) 2016-11-30 2024-12-06 ケース ウエスタン リザーブ ユニバーシティ １５－ｐｇｄｈ阻害剤とコルチコステロイドおよび／またはｔｎｆ阻害剤との組み合わせならびにその使用
WO2018145080A1 (en) 2017-02-06 2018-08-09 Case Western Reserve University Compositions and methods of modulating short-chain dehydrogenase activity
CA3059255A1 (en) 2017-04-07 2018-10-11 Case Western Reserve University Inhibitors of short-chain dehydrogenase activity for treating coronary disorders
WO2018218251A1 (en) 2017-05-26 2018-11-29 Case Western Reserve University Compositions and methods of modulating short-chain dehydrogenase activity
CN120463721A (zh) * 2018-11-21 2025-08-12 卡斯西部储备大学 调节短链脱氢酶活性的组合物和方法
JP2021134242A (ja) 2020-02-25 2021-09-13 株式会社アイティー技研 鉱物油精製方法及び装置
JP7574640B2 (ja) 2020-12-23 2024-10-29 株式会社リコー 画像処理装置、画像処理システム、方法およびプログラム

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005515182A (ja) 2001-11-16 2005-05-26 ファルマシア アンド アップジョン カンパニー リミティド ライアビリティー カンパニー 抗腫瘍剤により誘導される心臓毒性を処置するためのデクスラゾキサン
US20110269954A1 (en) 2008-12-30 2011-11-03 Hoon Cho Novel thiazolidinedione derivative and use thereof
WO2016168472A1 (en) 2015-04-14 2016-10-20 Case Western Reserve University Compositions and methods of modulating short-chain dehydrogenase activity

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LISA E. OLSON; ET AL，PROTECTION FROM DOXORUBICIN-INDUCED CARDIAC TOXICITY IN MICE WITH A NULL ALLELE OF 以下備考，CANCER RESEARCH，AMERICAN ASSOCIATION FOR CANCER，2003年10月15日，VOL:63，PAGE(S):6602 - 6606，https://cancerres.aacrjournals.org/content/63/20/6602.short，CARBONYL REDUCTASE 1

Also Published As

Publication number Publication date
JP2022141930A (ja) 2022-09-29
CN110891568A (zh) 2020-03-17
US11426420B2 (en) 2022-08-30
CA3059255A1 (en) 2018-10-11
WO2018187810A1 (en) 2018-10-11
EP3606520A4 (en) 2021-01-06
EP3606520A1 (en) 2020-02-12
AU2018249956A1 (en) 2019-11-14
AU2018249956B2 (en) 2024-05-23
JP2020516617A (ja) 2020-06-11
US20230165883A1 (en) 2023-06-01
US20200030348A1 (en) 2020-01-30

Similar Documents

Publication Publication Date Title
JP7178360B2 (ja) 冠状動脈障害を治療するための短鎖型デヒドロゲナーゼ活性の阻害剤
US20250295640A1 (en) Inhibitors of short-chain dehydrogenase activity for treating fibrosis
AU2018200368B2 (en) Compositions and methods of modulating 15-pgdh activity
JP7139308B2 (ja) 神経新生の促進及びニュ－ロン細胞死の阻害のための短鎖脱水素酵素活性の阻害剤
US20240174688A1 (en) Compositions and methods of modulating short-chain dehydrogenase activity
JP7595413B2 (ja) １５－ｐｇｄｈ阻害剤とコルチコステロイドおよび／またはｔｎｆ阻害剤との組み合わせならびにその使用
JP2018511581A5 (https=)
KR20220101071A (ko) 새로운 화합물
JP4538072B2 (ja) 新規フェニル酢酸誘導体
EP3327018B1 (en) 2-(octahydrocyclopenta[b]pyran-2-yl)1,3-thiazole-4-carboxylic acid derivatives and related compounds as ep2 agonists with intraocular pressure lowering activity

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200616

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200616

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210622

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210916

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211119

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211221

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20211222

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220329

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220727

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20220727

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20220809

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20220927

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20221004

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20221018

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20221114

R150 Certificate of patent or registration of utility model

Ref document number: 7178360

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250